Voices
Jad Chahoud
Jad Chahoud/moffitt.org

Jad Chahoud Shares an Article About a New Phase 2 Trial on First-Line Treatment for Advanced NSCLC

Jad Chahoud,  Genitourinary Medical Oncologist at Moffitt Cancer Center, shared an article by Shaodong Hong et al. published in Nature Medicine on X:

”Phase 2 OptiTROP-Lung01 Sacituzumab tirumotecan (ADC) + anti–PD-L1in 1L advanced NSCLC (no driver mutations):

  • ORR: 40% (q3w) vs 67% (q2w)
  • DCR: 85–92%
  • mPFS: 15.4 mo (q3w), NR (q2w)”

Title: First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial

Authors: Shaodong Hong, Qiming Wang, Ying Cheng, Yongzhong Luo, Xiujuan Qu, Haibo Zhu, Zhenyu Ding, Xingya Li, Lin Wu, Yan Wang, Sheng Hu, Enwen Wang, Anwen Liu, Yuping Sun, Yun Fan, Feng Ye, Kaihua Lu, Jian Fang, Yuping Shen, Xiaoping Jin, Junyou Ge, Li Zhang, Wenfeng Fang

You can read the Full Article here.

Jad Chahoud Nature Medicine

More posts featuring Jad Chahoud.

Anwen Liu cancer Enwen Wang Feng Ye Haibo Zhu Immunotherpy Jad Chahoud Jian Fang Junyou Ge Kaihua Lu Li Zhang Lin Wu Lung cancer Nature Medicine OncoDaily Oncology Qiming Wang Shaodong Hong Sheng Hu Wenfeng Fang Xiaoping Jin Xingya Li Xiujuan Qu Yan Wang Ying Cheng Yongzhong Luo Yun Fan Yuping Shen Yuping Sun Zhenyu Ding